CMX001

DRUG4 trials

Sponsors

Jazz Pharmaceuticals

Conditions

Ebola VirusHealthyHepatic ImpairmentOutcomesSurvival Rates

Phase 1

Comparative Bioavailability and Effect of Food on CMX001 in Healthy Volunteers

CompletedNCT00780182

Jazz PharmaceuticalsHealthy

Start: 2008-10-31End: 2009-01-31Target: 24Updated: 2010-02-02

Safety and Pharmacokinetics of CMX001 in Impaired Hepatic Function and Healthy Subjects

CompletedNCT05391724

Jazz PharmaceuticalsHepatic Impairment

Start: 2011-02-28End: 2011-09-30Updated: 2022-05-26

Phase 2

An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease

WithdrawnNCT02271347

Jazz PharmaceuticalsEbola Virus

Start: 2014-10-31End: 2015-01-31Updated: 2015-02-02

Unknown Phase

The Chimerix CMX001 Registry

TerminatedNCT02167685

Jazz PharmaceuticalsOutcomes, Survival Rates

Start: 2014-01-31End: 2019-05-10Target: 550Updated: 2019-05-17

Related Papers

Experimental Treatment of Ebola Virus Disease with Brincidofovir

PLoS ONE2016-09-0997 citations

Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea

PLoS Medicine2016-03-01477 citations